Liver Steatosis clinical trials

Explore recruiting liver steatosis clinical trials.

Recruiting liver steatosis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Liver Steatosis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Impact of Doravirine in Liver Steatosis and Fibrosis in PLWH. A pilot, proof of concept study (DORALI Study)

Spain

Therapeutic use (Phase IV) EU CTIS Study details

The effect of transdermal 17-β-estradiol/progesterone supplementation on glucose regulation in peri- and postmenopausal women with type 1 and type 2 diabetes

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

Effects of NNC0194-0499 alone and in combination with semaglutide, of semaglutide alone, and of cagrilintide alone and in combination with semaglutide on liver damage and alcohol use in people with alcohol-related liver disease

Germany, Greece, Bulgaria, France, Denmark, Czechia +4 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Severe Hypertriglyceridemia (SHTG)

Spain, Poland, Hungary, Latvia, Austria, Bulgaria +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Effect of Mediterranean diet combined with intermittent fasting on liver fibrosis compared to naltrexone/bupropion (Mysimba) in people with cardiometabolic risk factors

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

SETmelanotide to improve hypothalamic function in the ROHHAD-syndrome; a proof of concept study in a small mono-center cohort: the ROH-SET Study

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Liver Steatosis trials by city

Liver Steatosis in Toronto Liver Steatosis in Vancouver Liver Steatosis in Montreal Liver Steatosis in Calgary Liver Steatosis in Edmonton Liver Steatosis in Ottawa Liver Steatosis in Winnipeg Liver Steatosis in Quebec City Liver Steatosis in Hamilton Liver Steatosis in Kitchener Liver Steatosis in London Liver Steatosis in Halifax Liver Steatosis in New York Liver Steatosis in Los Angeles Liver Steatosis in Chicago Liver Steatosis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease